Curexa - East made compounded drugs under insanitary conditions, with contamination and inadequate cleaning, FDA says.
What happened
FDA inspected the Curexa - East facility in Egg Harbor Township, NJ, from August 29 to September 9, 2022, and issued a Form FDA 483. Investigators observed non-microbial contamination in the production area and found drugs requiring special handling (hazardous drugs) were produced without adequate cleaning of utensils, components, or containers to prevent cross-contamination. FDA reviewed the company’s October 7, 2022 response and said several cleaning fixes were not adequately documented or were deficient, including residue in hoods, a discolored HEPA filter, blue residue in an air conditioner above production areas, and V-blender residue.
What FDA found
Drug products were prepared, packed, or held under insanitary conditions—dirty conditions that can contaminate them with filth or make them injurious to health.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Non-microbial contamination was observed in the production area.
FDCA section 501(a)(2)(A)Drugs requiring special handling (hazardous drugs) were produced without adequate cleaning of utensils, components, or containers to prevent cross-contamination.
FDCA section 501(a)(2)(A)Blue residue remained in an air conditioning unit above production areas, posing a possible product contamination risk.
FDCA section 501(a)(2)(A)Residue on the V-blender was not adequately addressed; FDA said wiping with the stated agent alone did not assure removal of product residue.
FDCA section 501(a)(2)(A)The firm used household detergent to clean in-process materials and equipment without establishing that its cleaning process removes detergent residues.
FDCA section 501(a)(2)(A)
What FDA wants
Within 15 working days of receiving the letter, notify FDA in writing of the specific steps taken to address the violations, including an explanation of each step, related documentation, and steps to prevent recurrence. If the matter cannot be fully addressed within that time, state the reason for delay and the timeframe for completion.
Who should pay attention
- patients receiving compounded drugs from this pharmacy
- clinics and pharmacies that source compounded drugs from Curexa
- compounding pharmacies with similar hood, HEPA filter, and cleaning practices
This is a summary. Read the original letter on fda.gov.